Alexion Pharmaceuticals SVP Frank J. Wright Sells 1,098 Shares (ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) SVP Frank J. Wright sold 1,098 shares of the company’s stock on the open market in a transaction dated Friday, February 7th. The stock was sold at an average price of $155.57, for a total transaction of $170,815.86. Following the sale, the senior vice president now directly owns 19,670 shares in the company, valued at approximately $3,060,062. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million.
A number of analysts have recently weighed in on ALXN shares. Analysts at Deutsche Bank raised their price target on shares of Alexion Pharmaceuticals from $125.00 to $205.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Zacks upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Friday. They now have a $189.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals in a research note to investors on Tuesday, February 4th. They now have a $170.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $159.61.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.